# Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine

> **NCT01735006** · PHASE3 · COMPLETED · sponsor: **Xiamen University** · enrollment: 7372 (actual)

## Conditions studied

- Cervical Intraepithelial Neoplasia
- Cervical Cancer
- Vaginal Intraepithelial Neoplasia
- Vulvar Intraepithelial Neoplasia
- Persistent Infection

## Interventions

- **BIOLOGICAL:** HPV Vaccine
- **BIOLOGICAL:** HEV vaccine

## Key facts

- **NCT ID:** NCT01735006
- **Lead sponsor:** Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-22
- **Primary completion:** 2019-08-01
- **Final completion:** 2019-10-18
- **Target enrollment:** 7372 (ACTUAL)
- **Last updated:** 2020-02-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01735006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01735006, "Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01735006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*